MMWR Recomm Rep. 1996 Dec 27;45(RR-15):1-30.
This report provides recommendations for use of the newly licensed hepatitis A vaccines (HAVRIX, manufactured by SmithKline Beecham Biologicals, and VAQTA, manufactured by Merck & Company, Inc.) in persons > or = 2 years of age and updates previous recommendations for use of immune globulin (IG) for protection against hepatitis A (superseding MMWR 1990;39[No. RR-2]:1-5). For preexposure protection, hepatitis A vaccine can now be used instead of IG in many circumstances; for postexposure prophylaxis, the recommendations for IG use are unchanged.
本报告针对新获许可的甲型肝炎疫苗(史克必成生物制品公司生产的HAVRIX和默克公司生产的VAQTA)在2岁及2岁以上人群中的使用提供了建议,并更新了此前关于使用免疫球蛋白(IG)预防甲型肝炎的建议(取代了《发病率与死亡率周报》1990年;39[第RR - 2号]:1 - 5)。对于暴露前预防,在许多情况下现在可以使用甲型肝炎疫苗替代IG;对于暴露后预防,IG的使用建议不变。